Program
Capecitabine
Also written as “capecitabine”, “capecitabine [Xeloda]” and “Utidelone in combination with capecitabine”.
Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Neoplasms, led by 13 companies.
Drug pageCapecitabine: every studyMany companies study it; this page follows only the 72 they lead. All 947 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 430 open or running | phase 4since Jul 12, 2004 | May 2, 2000 | none ahead |
| Sanofiits history only | 90 open or running | phase 3since Apr 20, 2004 | Apr 20, 2004 | none ahead |
| R-Pharmits history only | 60 open or running | phase 3since Mar 26, 2004 | Nov 12, 2002 | none ahead |
| Novartisits history only | 41 open or running | phase 3since Jul 26, 2007 | Jul 26, 2007 | Apr 14, 2027phase 2 · NCT06247995 |
| Qilu Pharmaceuticalits history only | 21 open or running | phase 2since Jun 1, 2024 | Feb 10, 2018 | none ahead |
| Academy Military Medical Science, Chinaits history only | 10 open or running | phase 2since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| Bio-Cancer Treatment Internationalits history only | 10 open or running | phase 2since Mar 14, 2014 | Mar 14, 2014 | none ahead |
| EBG MedAustronits history only | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| iOMEDICOits history only | 10 open or running | phase 4since Aug 28, 2014 | Aug 28, 2014 | none ahead |
| NovoCureits history only | 10 open or running | no phasesince Feb 20, 2020 | Feb 20, 2020 | none ahead |
| Pharmatech Oncology | 10 open or running | phase 2since Nov 9, 2001 | Nov 9, 2001 | none ahead |
| Pierre Fabreits history only | 10 open or running | phase 2since Oct 3, 2016 | Oct 3, 2016 | none ahead |
| Prologue Research Internationalits history only | 10 open or running | phase 3since Jun 5, 2003 | Jun 5, 2003 | none ahead |
Also a collaborator on its studies: Exelixis, Clovis Oncology, Johnson & Johnson, Parexel, Baili-Bio (Chengdu) Pharmaceutical, Zai Lab, Chengdu Biostar Pharmaceuticals, Regeneron Pharmaceuticals, GlaxoSmithKline and Yakult Honsha.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pharmatech Oncology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2001First study: phase 2 study in Breast NeoplasmsFirst studyNCT00026442 · United States
TargetBeta
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule
Other programs on TYMS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 141 |
| Fluorouracilrule | Sanofi | phase 4 | 82 |
| Tegafurrule | Otsuka | phase 3 | 25 |
Studies
The one study Pharmatech Oncology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00026442Breast Neoplasms · United States | 2 | UNKNOWN |
How it is read
Names in the registry
- “Capecitabine”, 62 entries
- “capecitabine”, 16 entries
- “capecitabine [Xeloda]”, 12 entries
- “Utidelone in combination with capecitabine”, 3 entries
- “Capecitabine [Xeloda]”, 3 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 44 studies
- Colorectal Neoplasms, 21 studies
- Stomach Neoplasms, 16 studies
- Pancreatic Neoplasms, 6 studies
- Neoplasms, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.